Harvard Bioscience, Inc. (NASDAQ:HBIO) Director George Uveges sold 35,054 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $4.61, for a total value of $161,598.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Harvard Bioscience, Inc. (HBIO) traded up $0.20 during trading on Monday, reaching $4.80. The company had a trading volume of 144,131 shares, compared to its average volume of 167,103. Harvard Bioscience, Inc. has a 1-year low of $2.25 and a 1-year high of $5.20. The firm has a market cap of $160.45, a price-to-earnings ratio of -240.00 and a beta of 1.32. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40.
Harvard Bioscience (NASDAQ:HBIO) last announced its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.05. Harvard Bioscience had a positive return on equity of 2.38% and a negative net margin of 0.85%. The business had revenue of $27.46 million for the quarter, compared to analyst estimates of $26.60 million. analysts anticipate that Harvard Bioscience, Inc. will post 0.11 EPS for the current fiscal year.
Several equities analysts recently issued reports on HBIO shares. Zacks Investment Research upgraded Harvard Bioscience from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Thursday. Janney Montgomery Scott raised their target price on Harvard Bioscience from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, Benchmark raised their target price on Harvard Bioscience from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $7.75.
WARNING: “Harvard Bioscience, Inc. (HBIO) Director George Uveges Sells 35,054 Shares” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.themarketsdaily.com/2018/03/12/harvard-bioscience-inc-hbio-director-george-uveges-sells-35054-shares.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.